Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProQR Therapeutics N.V.PRQR · Entity 5946 | Director | June 02, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProQR Therapeutics N.V.
Report date June 02, 2026 · Filed June 30, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.42 · Expires 2036-06-01 | Direct | 14,595 |
Reported balance
After 2026-06-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 14,595 · Balance 14,595 F1: The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy. F2: 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.
F2: 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 3, 2026 20:01 UTC | ProQR Therapeutics N.V. PRQR · Entity 5946 | GrantShare Option (Right to Buy) · Derivative | 14,495 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001104659-26-070090 · tm2616802-1_4seq1.xml · derivative · entry 1 Hinsch Gylvin Lykke · CIK 0002135139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,495 Underlying: Ordinary Shares · 14,495 shares Expires 2036-06-01 F1 · derivative.exercise_price: The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 02, 2026 Filed Jun 30, 2026 20:02 UTC Amendment | ProQR Therapeutics N.V. PRQR · Entity 5946 | GrantShare Option (Right to Buy) · Derivative | 14,595 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001104659-26-079319 · tm2619428-2_4aseq1.xml · derivative · entry 1 Hinsch Gylvin Lykke · CIK 0002135139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,595 Underlying: Ordinary Shares · 14,595 shares Expires 2036-06-01 F1 · derivative.exercise_price: The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.